SACRAMENTO, California, April 11, 2019 /PRNewswire/ — The editors and judges of Fast Company Magazine selected Anpac Bio-Medical Science Company‘s, “Cancer Differentiation Analysis” (CDA) Liquid Biopsy technology as an international, 2019 Health & Wellness “World Changing Ideas Award” Honorable Mention recipient.

Fast Company Magazine selected Anpac Bio-Medical Science Company’s “Cancer Differentiation Analysis” (CDA) Liquid Biopsy technology as an international, 2019 Health & Wellness “World Changing Ideas Award” Honorable Mention recipient this week. Anpac Bio’s CDA identifies 20+ cancers with a single, standard blood test – usually at the diseases’ earliest stages. Anpac Bio was selected by Fast Company judges tasked with recognizing, “…finished products and brave concepts that make the world better.”

Joining other “World Changing Ideas Award” (WCI) honorees such as: IBM, Intel, Amazon, NIKE, Boston Children’s Hospital, Abbott, Microsoft, National Geographic, Gilead, Fitbit, Google, Siemens, Thermo Fisher Scientific, and The Bill & Melinda Gates Medical Research Institute, among others, Anpac Bio was recognized by Fast Company judges tasked with identifying, “…finished products and brave concepts that make the world better.”

WCI award recipients were selected from among over 2,000 nominations worldwide, based on feasibility and the potential for impact; and with a goal of awarding, “ingenuity and fostering innovation.”

Previously described as “game changing”, and receiving the, “Breakthrough Innovation Award”, at the World Nobel Prize Laureate Summit; and named, “Most Promising Cancer Screening Company”, at the Global Precision Medicine Industry Awards; Anpac Bio was also recently selected by the United States Department of Commerce as the, “Minority Health Firm of the Year”, due to the company’s remarkable, CDA liquid biopsy technology.

Anpac Bio pioneered liquid biopsy cancer screening research. Comprehensive research validity data from 140,000+ cases (to date), and independently-corroborated by world-renowned hospitals and cancer research leaders, demonstrate CDA diagnostics consistently detects over 20 types of cancer, with 80%-90% sensitivity and specificity rates — usually at the diseases’ earliest stages. And it does so without any harmful patient side effects; generating far fewer “false positives”; at a cost substantially lower than traditional testing (such as imaging); and generating results within minutes of sample submission. Anpac Bio has filed over 200 CDA-related patent applications worldwide – 110 issued in 20 countries and regions (to date).

“Our Anpac Bio team is very proud to receive the ‘World Changing Ideas’ recognition from Fast Company,” states Dr. Chris Yu, Anpac Bio CEO. “We believe the most important, world changing health ideas must be related to the early detection and prevention of disease. Our CDA technology was developed to achieve those goals. And we are now saving an average of two patients every week by catching their cancer at the earliest stages. We thank Fast Company for this great honor.”

For further information: AnpacBio.com.

Fast Company Magazine judges selected Anpac Bio-Medical Science Company’s, “Cancer Differentiation Analysis” (CDA) Liquid Biopsy technology as an international, 2019 Health & Wellness “World Changing Ideas Award” (WCI) Honorable Mention recipient. Anpac Bio’s CDA identifies 20+ early-stage cancers with a single blood test. WCI award recipients were selected from over 2,000 nominations worldwide, based on the Ideas’ feasibility; potential for impact; and demonstrated ingenuity and innovation.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, “Cancer Differentiation Analysis” liquid biopsy technology that effectively reinvents cancer screening and early detection. Anpac Bio’s proprietary CDA medical devices analyze simple, standard, non-invasive “Blood Biopsies” – resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 120,000 cases to date demonstrate CDA’s research validity achieving an average sensitivity and specificity rate range of 75%-90% for 28+ different types of cancer — often identifying the type and location of threatening, diseased cancer cells before they form into tumors. Fully-commercialized and the only company earning liquid biopsy revenue globally, Anpac Bio has filed 250+ CDA-related Patents; 101+ issued to date worldwide. For more information: AnpacBio.com.

Photo – https://mma.prnewswire.com/media/870121/Fast_Company_World_Changing_Ideas_Award.jpg
Photo – https://mma.prnewswire.com/media/870120/2019_Health_and_Wellness_World_Changing_Ideas_Award.jpg 
Logo – https://mma.prnewswire.com/media/318127/anpac_bio_medical_science_co.jpg

-RayVio’s new XR 308 nm UVB LED can lower treatment costs and improve treatment processes

HAYWARD, California, April 11, 2019 /PRNewswire/ — RayVio Corp., an advanced health and hygiene company, is shipping its new, 308 nm XR UVB LEDs and supporting the development of phototherapy treatments for skin diseases. RayVio’s new XR UV LEDs enable targeted therapies, smaller and lower cost treatment devices, and superb reliability. Available directly from Digi-Key as an emitter or pre-mounted on a star board for easy development and product integration, RayVio’s new LEDs deliver 13 mW at 100 mA and are rated for up to 10,000 hours of continuous use.

RayVio’s XR 308 nm UVB LEDs are key to improved treatment options for Psoriasis and Vitiligo.

“UV Treatment of Psoriasis and Vitiligo have been limited because of the size and cost of the equipment as well as the risk to healthy surrounding tissue,” said Yitao Liao, Chief Innovation Officer and co-founder at RayVio. “Excimer laser systems address the targeting of treatment to avoid damaging healthy skin, but the systems are bulky and very expensive. Our 308 nm UV LEDs are being put into compact, handheld devices that are portable.”

RayVio has achieved record-setting performance of 300 mW output at 308 nm from a single UV LED package and is already sampling this option to customers. Its advances in LED technology for phototherapy and Vitamin D production are also advancing and the company is preparing a more powerful, 293 nm emitter in 2019.

RayVio’s work in the UVB range for phototherapy applications complements its pioneering UVC LED technology that offers leading performance for disinfection and sterilization applications like water purification.

About RayVio Corp.
RayVio Corp. is an advanced health and hygiene company that delivers clean water and environments. RayVio helps protect billions from germs and creates new markets and revenue streams by enabling a new class of products. Its powerful and efficient UV LED technology can be integrated into a variety of applications, powering versatile on-demand solutions that give consumers control over health without chemicals or costly consumables. To learn more, please visit www.rayvio.com.

Photo – https://mma.prnewswire.com/media/858671/XR_308_nm.jpg
Logo – https://mma.prnewswire.com/media/372098/RayVio_Corporation_Logo.jpg

Source: RayVio Corp.

Source: China Jo-Jo Drugstores, Inc.

Business models around transitional care management offer tangible growth opportunities, finds Frost & Sullivan

SANTA CLARA, Califronia, April 10, 2019 /PRNewswire/ — Every year, across the United States (US), close to 50 percent of patients fail to understand treatment plans and care management guidelines, and approximately 20 percent of them switch providers due to a lack of trust in their care teams. Next-generation patients prefer having access to personalized clinical information on the go, requiring caregivers to coordinate medical insight across the care continuum more efficiently than ever. Almost 70 percent of patients reported feeling fully satisfied when they received coordinated care from a provider-designated team that appears confident in identifying the right intervention strategies and delivering episodic medical support compassionately. However, such services cannot be scaled without the contribution of progressive digital health solutions. As a result, the care coordination software market is poised to witness significant traction from payers, hospitals and physician practices across the US. This is expected to drive the $1.55 billion care coordination software market toward $3.18 billion by 2022 at a compound annual growth rate of 15.4 percent.

“The care coordination software market is embracing large-scale innovation, aided by advanced technologies such as AI and blockchain, which support data interoperability and normalization within a defined clinical network,” said Koustav Chatterjee, Industry Analyst, Transformational Health. “The growing need to auto-trigger worklists and personalize intervention plans for complex patient populations will further drive investments in care coordination IT (CCIT).”

Frost & Sullivan’s recent analysis, US Care Coordination Software Market, Forecast to 2023, examines the adoption drivers across a variety of settings. It also presents the challenges impacting the market and the outlook for the adoption of care coordination software among three key customer segments. It presents forecasts for the overall market growth over a six-year period and opportunities within the total market.

For further information on this analysis, please visit: http://frost.ly/3ck.

“While regulatory hurdles had hindered the adoption of CCIT in the past, the latest US policies advocating the Promoting Interoperability initiative by Centers of Medicare and Medicaid Services (CMS), the cross-continuum interoperability, are expected to accelerate the adoption of both software and service solutions,” noted Chatterjee. “Business models will remain largely centered on transitional care management, and chronic condition management is highly regulated under various value-based reimbursement programs. Legacy electronic health record (EHR) platforms, which allow third-party integration with CCIT to remain interoperable in the front end, will thrive. Collaboration with traditional ICT vendors such as Microsoft, Apple, and Salesforce is also expected by both payers and providers.”

For additional growth opportunities, CCIT vendors are likely to:

• Encourage the integration of disparate medical workflows by demonstrating accrued revenue, saved costs, and improved outcomes.
• Automate the process of matching patients with their care teams. Care managers need to employ IT enablers so that they can proactively reach out to patients’ caretakers and provide insights to help make more informed, data-driven decisions.
• Manage patients’ clinical and financial experience through IT, enabling the sharing or exchanging of information required to make favorable decisions.
• Deliver robust care coordination software products that offer end-to-end referral management capabilities.
• Highlight financial gaps in the network and identify patients who can generate incremental revenue for caregivers.
• Introduce a digital command center to auto-attribute care managers, who will be responsible for delivering, monitoring, and benchmarking care plan adherence both manually and digitally for patients.

US Care Coordination Software Market, Forecast to 2023 is part of Frost & Sullivan’s global Digital Health Growth Partnership Service program.

About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

US Care Coordination Software Market, Forecast to 2023
9AB9-48

Contact:
Mariana Fernandez
Corporate Communications
T: +1 210 348 10 12
T: +54 11 4778 3540
E: Mariana.Fernandez@frost.com

http://ww2.frost.com

Photo – https://mma.prnewswire.com/media/869666/Care_Coordination_Software.jpg

— Expands approved indication in Australia to include use of INOmax for perioperative pulmonary hypertension in conjunction with cardiovascular surgery in neonates through adults —

SYDNEY, April 11, 2019 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that INOmax^™ (nitric oxide) gas, for inhalation has received regulatory approval in Australia by the Australian Therapeutic Goods Administration (TGA) for perioperative pulmonary hypertension in adults in conjunction with cardiovascular surgery. INOmax was previously approved for this same indication in neonates through adolescents up to age 17, and is also approved in Australia for the treatment of hypoxic respiratory failure (HRF) associated with pulmonary hypertension, a potentially life-threatening condition, in term and near-term newborns (>34 weeks).

INOmax nitric oxide is a vasodilator that opens (dilates) blood vessels, improving oxygen uptake and blood flow. It is used in conjunction with ventilator support and other appropriate agents. INOmax decreases pulmonary arterial pressure.

“This expanded approval of INOmax in Australia for cardiovascular surgery in adults is an important milestone for Mallinckrodt, confirming the benefit this therapeutic option can bring to perioperative pulmonary hypertension patients,” said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer, Mallinckrodt. “We continue to focus on improving outcomes for underserved patients with severe and critical conditions, and this is an example of those efforts making a difference. There is a tremendous global need for therapies for patients undergoing cardiac surgery. We look forward to helping meet these needs.”

ABOUT INOMAX
INOmax (nitric oxide) gas, for inhalation, is approved by the TGA in Australia for perioperative pulmonary hypertension in conjunction with cardiovascular surgery in neonates through adults, and for the treatment of HRF associated with pulmonary hypertension, a potentially life-threatening condition in newborns. It is approved in certain other countries for specified indications as well.

Before prescribing please refer to the full Product Information which is available from Mallinckrodt’s Australian subsidiary by phone at 1300 198 565 or from this link.

Australia Minimum Product Information: INOmax (nitric oxide) gas, for inhalation

Indications: INOmax, in conjunction with ventilatory support and other appropriate agents, is indicated:

• For the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.
• To selectively decrease pulmonary arterial pressure in patients with perioperative pulmonary hypertension in conjunction with heart surgery.

Contraindications: Neonates known to be dependent on right-to-left or significant left-to-right shunting of blood; hypersensitivity to the active substance or any of the excipients.

Special Warnings and Precautions: Do not use INOmax undiluted; INOmax must be diluted by the ventilator gas flow to a concentration not greater than 20ppm; use an approved nitric oxide gas delivery system provided by the sponsor that meets the criteria specified in the Dosage and Administration Section. INOmax should not be discontinued abruptly, as it may result in rebound pulmonary hypertension syndrome; weaning should be performed with caution. Concentrations of methaemoglobin in the blood should be measured within one hour after initiation of INOmax therapy, using an analyser which can reliably distinguish between foetal haemoglobin and methaemoglobin; if methaemoglobin is >2.5%, the INOmax dose should be decreased and the administration of reducing agents may be considered. The dose of nitric oxide should be reduced if the concentration of nitrogen dioxide exceeds 0.5 ppm. The benefit/risk of using inhaled nitric oxide in patients with clinically significant left ventricular dysfunction should be evaluated on a case-by-case basis due to possible increased rate of serious adverse events. Treatment with inhaled nitric oxide might aggravate cardiac insufficiency in a situation with left-to-right shunting; prior to the administration of nitric oxide, pulmonary artery catheterisation or echocardiographic examination of central haemodynamics is recommended. Animal models have shown that nitric oxide may interact with haemostasis, resulting in an increased bleeding time. Long-term monitoring of babies post-treatment is recommended.

Use in pregnancy: Category B2.

Interactions with other medicines: Increased risk of methaemoglobinaemia with co-administration of nitric oxide donor compounds (e.g., sodium nitroprusside, nitroglycerine) or drugs that increase methaemoglobinaemia (e.g., prilocaine).

Adverse effects: Formation of methaemoglobin >5% has been observed. Rapid rebound reactions such as intensified pulmonary vasoconstriction and hypoxaemia after sudden withdrawal have been described, precipitating cardiopulmonary collapse. A clinical study in neonates reported the following adverse effects with incidence of at least 5%: thrombocytopenia, hypotension, bacteraemia and/or local infection, rebound hypoxaemia as very common (> 10% incidence) and atelectasis, haematuria, hyperglycaemia, hypokalaemia, hyperbilirubinaemia, stridor and cellulitis as common (1-10% incidence). No additional adverse events were identified in the paediatric cardiac surgery indication trials.

Dosage and Administration: INOmax should only be used after respiratory support is optimised including the use of surfactant in the neonatal intensive care unit setting, or only after conservative support has been optimised in the cardiac surgery setting. The maximum recommended dose of INOmax is 20 ppm. The delivery system must provide a constant inhaled INOmax concentration irrespective of the ventilator. As dosing is complex, refer to the full prescribing information for dosage, weaning, administration, and monitoring recommendations and methods. Prescribing information last amended 29 March 2019.

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. Its Specialty Generics and Amitiza reportable segment includes specialty generic drugs, active pharmaceutical ingredients and AMITIZA^® (lubiprostone). To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Cautionary Statements Related to Forward-Looking Statements

This release includes forward-looking statements concerning INOmax. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the “Risk Factors” section of Mallinckrodt’s most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

CONTACTS

Media
Daniel Yunger
Kekst CNC
212-521-4879
mallinckrodt@kekstcnc.com

Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2019 Mallinckrodt. 4/19

Logo – https://mma.prnewswire.com/media/167103/mallinckrodt_plc_logo.jpg

ISNES, Belgium, April 10, 2019 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. Volition has also issued a Company Update Report; a downloadable version of which is available here

“It has been a busy quarter with the public announcement of a number of initiatives and we were delighted to have the opportunity to discuss our plans at the Capital Markets Day event today,” commented Chief Executive Officer, Cameron Reynolds. “We would like to thank all those who attended, especially our speakers Professor Axel Imhof of Ludwig-Maximilians University of Munich and Associate Professor Heather Wilson-Robles of Texas A&M University.”

To view the opening video shown at today’s event please click here 
A highlights video from the day will be released on Wednesday, April 10.

Following recently announced preliminary results from two proof of concept studies in lung cancer, Volition has signed a Memorandum of Understanding with the prestigious National Taiwan University through its wholly-owned subsidiary, Belgian Volition SPRL (“Belgian Volition”), to conduct a large-scale lung cancer study. Principal Investigator Professor Chen Jin-Shing commented: “The early data of the Nu.Q^TM technology platform is promising but clearly larger scale studies are required. Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test or for a triage test which can improve the specificity of the Low-Dose CT scan currently used.”  Volition expects to release preliminary data relating to the first 600 patient samples in first quarter of 2020.

Volition has also executed a nonbinding Memorandum of Understanding with Shanghai Fosun Long March Medical Science Co., Ltd. with an expectation of negotiating and entering into a binding agreement to help facilitate the entrance of the Nu.Q^TM platform into China. Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, commented: “We are happy to be able to announce this Memorandum of Understanding with Fosun Long March because, in addition to our plans to undertake clinical studies in colorectal cancer, lung cancer and ovarian cancer, we are also planning to jointly explore the development of Nu.Q^TM assays utilizing Fosun’s LUMIART-II Automated Chemiluminescence Immunoassay System, which could provide us with an additional platform for the Chinese market.”

In an announcement earlier today, Volition revealed that it has also entered into a nonbinding Memorandum of Understanding (“MOU”) through Belgian Volition with Texas A&M University, a member of The Texas A&M University System. Pursuant to the terms of the MOU, the parties will explore the feasibility of a collaborative research relationship.  Any such relationship is subject to the negotiation of terms and conditions and the entry into a final binding agreement.  The MOU contemplates that Belgian Volition would form a new subsidiary in the United States to focus on the veterinary diagnostic market utilizing its Nucleosomics^TM technology (“Vetco”) and Texas A&M University would collaborate on the research and development of veterinary diagnostic products and is interested in negotiating a shareholding in Vetco.

Dr. Jason Terrell, Chief Executive Officer of Volition America Inc., stated: “From a commercial point of view, we are extremely excited about the possibility of offering Nu.Q^TM Vet tests to animal owners and veterinarians.  There are currently no accurate, simple, affordable cancer screening or diagnostic tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage of their life. With pricing currently expected to be between $100–$200 per test, we believe that this is a multi-billion-dollar opportunity. We aim to have the first Nu.Q^TM Vet product on the market in the U.S. in 2020.” 

About Volition

Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics^TM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition’s research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market.

For more information about Volition, visit Volition’s website (http://www.volitionrx.com) or connect with us via:

Twitter: https://twitter.com/volitionrx 
LinkedIn: https://www.linkedin.com/company/volitionrx 
Facebook: https://www.facebook.com/VolitionRx/ 
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition’s website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition’s website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to the establishment of a collaborative research relationship and the negotiation and execution of a binding agreement with Texas A&M University, the negotiation and execution of binding agreements with each of the National Taiwan University and Shanghai Fosun Long March Medical Science Co., Ltd., the effectiveness of Volition’s blood-based diagnostic tests as well as Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD or the veterinary markets; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics^TM, and Nu.Q^TM and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-hosts-capital-markets-day-at-the-new-york-stock-exchange-and-issues-company-update-report-300828427.html

The company’s international safety standards, strategic partnerships and Africa-centric design give it a competitive edge in the regional market

LONDON, April 10, 2019 /PRNewswire/ — Based on its recent analysis of the African mobile health market, Frost & Sullivan recognises Kenya-headquartered AfriDOKTA with the 2018 African Customer Value Leadership Award for its hybrid telemedicine/mHealth platform. AfriDOKTA is a subsidiary of eHealth Solutions LLC, a global company based in the United States, which is a leader in developing outcome-based electronic healthcare solutions. Through its telemedicine/mHealth solution, AfriDOKTA aims to deliver first class and world class healthcare to African countries and other low and middle-income countries challenged with major health burdens, regardless of their location and socioeconomic status.

2018 African Mobile Health Customer Value Leadership Award

“The Kenyan government has been rolling out universal healthcare as one of its four major pillars of growth and is investing in infrastructure to improve connectivity, which, in turn, is boosting the potential of mHealth solutions. AfriDOKTA is driving Kenya’s leadership in the telemedicine and mobile app space to propel its country-agnostic platform to the rest of Africa,” said Nicholas Burger, Ph.D., Consultant at Frost & Sullivan. “The AfriDOKTA platform is a 10-key app that can replicate in any country across the globe. Its user-friendly interface and simple set-up make it ideal for use among patient populations with a smart phone.”

Unlike most mHealth platforms in Africa, AfriDOKTA complies with international data security standards and adheres to the US-based Health Insurance Portability and Accountability Act (HIPAA). The company also applies Health Level 7 (HL7), SNOMED, and DICOM standards, which are a set of international principles used for the transfer of clinical data between various software and electronic applications. AfriDOKTA’s use of international standards for storing, accessing, and processing medical images and related information is a strong competitive differentiator in the market.

AfriDOKTA works with community health workers (CHWs), particularly in both urban,and remote areas, to train people to use smartphones to access healthcare services and explain the importance of taking control of their health information. Additionally, the app gives users referrals to vetted pharmacies and labs with certified medical professionals. CHWs encourage users to complete their personal profiles in a mobile electronic health record as it streamlines the consultation process and helps physicians make accurate and informed decisions. Finally, the platform uses algorithm-based clinical decision support to diagnose patients accurately based on their medical history and symptoms.

“AfriDOKTA works closely with leading pharmacies, hospitals, and allied healthcare services in several African countries. AfriDOKTA also welcomes partnerships with mobile phone service providers and smartphone manufacturers to develop healthcare app-integrated mobile phones for use among low-income population groups across Africa,” noted Dr. Burger. “These strategic collaborations, product benefits, and focus on security will ensure that the company continues to deliver top value to end users.”

AfriDOKTA welcomes Investors and venture capitalists interested in driving a strategic, first-mover advantage on the African continent.

Each year, Frost & Sullivan presents this award to the company that demonstrates excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognises the company’s unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.

Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About AfriDOKTA

Led by Dr John Gachago, Kigen Kandie, Michael Ranneberger, Ken Saul,and Dr. Lawrence Adu and Maragaret Bekker, AfriDOKTA is a team of professionals passionate about transforming the delivery of healthcare in Africa through people, processes and technology. The organization’s mission is three fold; transforming access to healthcare on the African continent; helping African nations meet SDG3 goals; and facilitating the attainment of affordable Universal Healthcare. AfriDOKTA maintains offices in both the US and Kenya. In the US HQ known as eHealth Solutions LLC and in Kenya as E-Health Solutions Ltd,  AfriDOKTA seeks to partner with African and other LMIC Ministries of Health as well as health system strengthening partners like USAID, DANIDA, DFID and various foundations like BMGF, Rockefeller and Ford Foundations to augment their efforts in healthcare in a data driven yet contextual fashion. We understand that many organizations seek to strengthen healthcare in Africa but the data needed is absent. AfriDOKTA fills that gap with its unique platform designed based on a combination of experience in the US health information technology market and consulting with multiple Ministries of Health in Africa on national eHealth strategy. By downloading the app from the Google play store or visiting https://AfriDOKTA.com anyone with a smart phone or internet access in Africa would have immediate access to first class and world class quality outpatient care.

Contact:

The AfriDOKTA Team
P: USA +1 617 752 1833 or KENYA + 254 719 229 524
E: customercare@afridokta.com OR mbekker@afridokta.com

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Bianca Torres
P: 1.210.477.8418
E: bianca.torres@frost.com

Photo – https://mma.prnewswire.com/media/858955/AfriDOKTA_Award.jpg

LONDON, April 8, 2019 /PRNewswire/ — Based on its recent analysis of the Middle Eastern market for artificial intelligence (AI)-enabled pain detection solutions, Frost & Sullivan recognises Dubai-based AIDirections with the 2019 Middle East Enabling Technology Leadership Award. The company’s one-of-a-kind AI-powered pain detection solution is revolutionising the market by using facial recognition technology, which is invaluable to impaired patients and people with minimal cognitive functions.

2019 Middle East Enabling Technology Leadership Award

“AIDirections combines the latest technologies, such as AI, deep learning, and facial recognition, with its proprietary algorithmic sentiment analysis solution to develop a new method for pain detection, monitoring, and verification,” said Sowmya Rajagopalan, Global Program Director at Frost & Sullivan. “The system, operable both at home and in hospitals, presents a clinically valid parameter known as the Prkachin and Solomon Pain Intensity metric to measure pain levels in individuals. By leveraging AI, the solution mitigates the subjectivity in the assessment, improves the accuracy of measurement, and supports superior treatment decision making and clinical outcomes.”

The solution has a wide scope of application among highly vulnerable patient populations, such as infants, children with developmental issues, people suffering from a stroke, and people who are unconscious and unable to express their pain. While several existing technological tools, such as mHealth, clinical wearables, and telemedicine, ensure optimal pain management in a home-based setting, patients still need to visit care facilities frequently to have their pain levels assessed. AIDirections’ tool emerges as an ideal solution in this environment because it integrates with the healthcare system’s existing telemedicine to create a better care experience for the patient.

AIDirections is working with several telemedicine companies to launch its offering officially as a holistic home-based solution in the growing Middle Eastern market and other developing regions. The company presents both server and cloud-based solutions that easily integrate with a hospital’s enterprise resource planning or customer relationship management software for easy deployment. The hospital pays a minimal onboarding fee, which includes installation and software setup. By reducing upfront costs, AIDirections helps clients achieve a faster return on investment.

“The solution uses AIDirections’ development framework based on industry standards while its plug-and-play methodology enables an extensive range of operational scenarios,” noted Rajagopalan. “For addressing an unmet market need with its highly innovative and cost-efficient technology, AIDirections richly deserves the 2019 Middle East Enabling Technology Leadership Award.”

Each year, Frost & Sullivan presents this award to a company that develops a pioneering technology that enhances current products and enables the development of new products and applications. The award recognises the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About AIDirections

AIDirections is a Dubai based company, which was established in response to the exciting developments in Artificial Intelligence (AI). The target market for AIDirections is the GCC, concentrating on UAE and Saudi Arabia. 

AIDirections’ value proposition is based on the development of use cases across a number of industries, particularly healthcare. We are providing consultancy for the best use of AI, and we are also developing a set of products through the use of computer vision.

The core staff of AIDirections brings together significant experience in research and development, technical standardization, management of research and development, development and implementation of national level strategies, futures study and work, international collaboration and consultancy.

AIDirections’ business areas are: 

• Training and awareness with regards to AI; 
• Assessment of AI Readiness and development of an AI Strategy;
• Consultancy to identify opportunities and risks related to the use of AI;  
• Provision of solutions for dedicated problems and customers, such as pain detection and sentiment analysis; and
• Provision of IoT solutions, e.g. for oil and gas or smart cities.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Tarini Singh
P: +91-20 6718 9725
E: Tarini.Singh@frost.com

Photo – https://mma.prnewswire.com/media/848014/AIDIRECTIONS_Frost_Sullivan_Artificial_Intelligence_Award.jpg

OSAKA, Japan, April 9, 2019 /PRNewswire/ — Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that GeneDesign, Inc. has joined the global organization. GeneDesign, a wholly owned Ajinomoto company, provides high quality and scalable custom oligonucleotides for the biopharmaceutical industry. The integration of GeneDesign’s services offerings with Aji Bio-Pharma’s small and large molecule capabilities in the US, Belgium and India strengthens the organization’s commitment to its customers to be a leading global CDMO with comprehensive capabilities.

In addition, on April 5^th, the company celebrated the grand opening of an approximately 2000 m² building, expanding oligonucleotide synthesis and supply capabilities (µg to 10 kg) to support customer needs. The new development center, located on the Osaka campus. provides a Class 100,000 clean area for cGMP manufacturing of oligonucleotide APIs, a multipurpose room to custom synthesize heavily modified oligonucleotides, and the world’s largest solid phase oligonucleotide synthesizer, OligoProcess, the first of this type of machine to be installed in Japan. The development center also houses process development labs to support manufacturing activities and R&D labs for the development of novel oligonucleotide manufacturing technologies.

“The integration of GeneDesign into Aji Bio-Pharma allows us to more seamlessly support our biopharmaceutical customers globally with a wide range of service offerings in one consolidated supply chain. This reinforces our Vision Statement of being a leading, trusted, innovative partner to our clients and our people,” said David Enloe, President and CEO of Ajinomoto Bio-Pharma Services. “Additionally, the opening of the new oligonucleotide API development center furthers our commitment to enhancing our service offerings and responsiveness to our customers’ needs.”

“We are extremely pleased to now be a part of the Aji Bio-Pharma,” said Kazuhiko Yuyama, CEO, GeneDesign. “Now, as part of a global CDMO, and with the addition of our new oligonucleotide API development center, we can further contribute to the health and well-being of patients worldwide.”

About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex^® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Learn more: www.AjiBio-Pharma.com

Logo – https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg

Patient monitoring helps patients have better outcomes and live longer

SANTA CLARA, California, April 7, 2019 /PRNewswire/ — Today is World Health Day, and this year’s theme is “Universal Health Coverage: Everyone, Everywhere—#HealthforAll.” An important aspect of “Health for All” is the role of technology, particularly patient monitoring (PM), which helps patients have better outcomes and live longer, healthier lives, even when access to hospitals and clinics is challenging. 

Patient monitoring has evolved from ad hoc to continuous monitoring of multiple parameters, causing a surge in the amount of unprocessed and unorganized data available to clinicians for decision-making. To extract actionable information from this data, healthcare providers are turning to big data analytics and other analysis solutions. Predictive analytics is becoming a particularly important technology, as it not only presents the current state of the patient’s health but also predicts future illnesses. The success of this technology, among many others, attracted $566.3 million in investments in 2018.

For further information on this analysis, please visit: http://frost.ly/3ba.

“As mHealth rapidly gains traction, wearables, telehealth, social media, and patient engagement are expected to find adoption among more than half of the population in developed economies by 2025,” said Sowmya Rajagopalan, Advanced Medical Technologies Global Director. “The patient monitoring market is expected to be worth more than $350 billion by 2025, as the focus is likely to move beyond device sales to solutions.”

Frost & Sullivan’s recent analysis, Patient Monitoring Industry—Analysis of Investment and Trends, 2018, offers an overview of the current investment trends and start-ups in select patient monitoring applications. It studies the future of patient monitoring across the continuum of care, the shifts in the market, and investment opportunities. It also presents the key disruptive technologies, application areas, drivers, restraints, as well as the top six Mega Trends.

“In the future, patient monitoring data will be combined with concurrent streams from numerous other sensors, as almost every life function will be monitored and its data captured and stored,” noted Rajagopalan. “The data explosion can be harnessed and employed through technologies such as Artificial Intelligence (AI), machine learning, etc., to deliver targeted, outcome-based therapies.”

In addition to these technologies, patient monitoring solution developers will look to incorporate disruptive technologies such as:

• Brain-computer interface (BCI): From treating and monitoring users with mobility or speech disabilities, BCI now monitors and measures health metrics for healthy people and uses the information to analyze a person’s psychological state or emotional, cognitive state.
• Wearables/Embedded/Biosensors: An increase in the chronic disease population and shift in focus from treatment to prevention drive this technology. Continuous glucose monitors, blood pressure monitors, pulse oximeters, and electrocardiogram monitors are some of the main applications.
• Smart Prosthetics/Smart Implants: These are crucial for patient management post-surgery or rehabilitation. They help in measuring the key parameters to support monitoring and early intervention to avoid readmission or complexities.
• Nano-robotics/Digital Medicine: Digital pills and nanorobots are designed to monitor medicine intake to address the expensive, long-standing issue of non-adherence.
• Advanced Materials/Smart Fabrics: This emerging field focuses on wound management, cardiac monitoring, and mental illness.

All these technologies and innovations are focused on providing real-time measurable value to the patient and healthcare institution. Future innovations will be aimed at mass personalization and availability.

Patient Monitoring Industry—Analysis of Investment and Trends, 2018 is part of Frost & Sullivan’s global Advanced Medical Technologies Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Patient Monitoring Industry—Analysis of Investment and Trends, 2018
9AB9-48

Contact:
Mariana Fernandez
Corporate Communications
T: +1 210 348 10 12
T: +54 11 4778 3540
E: Mariana.Fernandez@frost.com 

http://ww2.frost.com